Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical business focused on developing and commercializing therapeutic solutions for rare and orphan diseases. The company concentrates on conditions that currently lack approved therapies or have very restricted treatment options. Its lead investigational asset, QRX003, is a topical lotion formulated to address rare genetic skin disorders, primarily Netherton Syndrome as well as Peeling Skin Syndrome. Quoin is also developing additional pipeline candidates, including QRX008 for scleroderma and QRX009, which utilizes topical rapamycin formulations for multiple rare conditions. Its target patient populations consist of individuals diagnosed with these rare medical disorders.

The company operates across multiple international jurisdictions through clinical studies and partnerships. Its clinical trial footprint includes six sites in the United States, along with clinical sites and studies across the United Kingdom, Spain, France, Ireland, Austria, the Netherlands, and New Zealand. Additionally, Quoin maintains commercial distribution partnerships covering sixty-one countries outside its core commercial focus areas of the United States, Western Europe, and Japan. The provided text does not state the location of the company's headquarters.

Summary of the business section of Quoin Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had four full-time employees and two part-time employees.”